Recombinant anti-TNFα monoclonal antibody (Livzon Group)

重组人源化抗肿瘤坏死因子α单抗（丽珠集团）

Report date: 2024/05/21 14:56:41

Base Information

Drug NameRecombinant anti-TNFα monoclonal antibody (Livzon Group)
Drug Alias Name重组抗肿瘤坏死因子α单克隆抗体 - Livzon GroupRecombinant anti-TNF alpha monoclonal antibody (Livzon Group)重组人源化抗肿瘤坏死因子α单抗（丽珠）LZM-001AT-132(Livzon Group)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesLivzon Pharmaceutical Group Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLivzon Mabpharm Inc
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A